PUMA BIOTECHNOLOGY, INC. (PBYI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.09%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.09% | Share-based compensation / revenue. Period ending 2026-06-30. $7.14M ÷ $231.24M × 100 ≈ 3.09% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 231.24M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 7.14M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 30.44M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $231.24M | $7.14M | $30.44M | (m) | (m) | 3.09% | (m) | (m) |
| 2026-03-31 | (m) | $227.18M | $6.81M | $29.49M | (m) | (m) | 3.00% | (m) | (m) |
| 2025-12-31 | (m) | $228.37M | $6.94M | $37.30M | (m) | (m) | 3.04% | (m) | (m) |
| 2025-09-30 | (m) | $212.00M | $7.08M | $33.56M | (m) | (m) | 3.34% | (m) | (m) |
| 2025-06-30 | (m) | $238.06M | $7.46M | $46.06M | (m) | (m) | 3.13% | (m) | (m) |
| 2025-03-31 | (m) | $232.71M | $7.89M | $37.25M | (m) | (m) | 3.39% | (m) | (m) |
| 2024-12-31 | (m) | $230.47M | $8.24M | $30.97M | (m) | (m) | 3.58% | (m) | (m) |
| 2024-09-30 | (m) | $243.57M | $8.93M | $32.40M | (m) | (m) | 3.66% | (m) | (m) |
| 2024-06-30 | (m) | $219.14M | $9.42M | $18.91M | (m) | (m) | 4.30% | (m) | (m) |
| 2024-03-31 | (m) | $226.63M | $9.79M | $25.98M | $13.38M | (m) | 4.32% | 1.94× | Reported |
| 2023-12-31 | (m) | $235.64M | $10.25M | $32.64M | $13.33M | (m) | 4.35% | 2.45× | Reported |
| 2023-09-30 | (m) | $229.13M | $10.44M | $27.86M | $13.26M | (m) | 4.56% | 2.10× | Reported |
| 2023-06-30 | (m) | $230.12M | $10.73M | $21.67M | $12.86M | (m) | 4.66% | 1.68× | Reported |
| 2023-03-31 | (m) | $235.07M | $11.52M | $28.83M | $12.24M | (m) | 4.90% | 2.36× | Reported |
| 2022-12-31 | (m) | $228.03M | $11.83M | $23.72M | $11.59M | (m) | 5.19% | 2.05× | Reported |
| 2022-09-30 | (m) | $217.71M | $13.45M | $20.54M | $11.03M | (m) | 6.18% | 1.86× | Reported |
| 2022-06-30 | $60.21M | $206.86M | $14.90M | $9.19M | $11.21M | 29.11% | 7.20% | 0.82× | Reported |
| 2022-03-31 | $66.88M | $200.72M | $29.92M | $-19.60M | $12.02M | 33.32% | 14.91% | -1.63× | Reported |
| 2021-12-31 | $71.87M | $253.16M | $32.63M | $1.29M | $12.81M | 28.39% | 12.89% | 0.10× | Reported |
| 2021-09-30 | $81.86M | $250.35M | $37.85M | $-16.69M | $13.66M | 32.70% | 15.12% | -1.22× | Reported |
| 2021-06-30 | $86.37M | $254.86M | $41.14M | $-19.87M | $14.16M | 33.89% | 16.14% | -1.40× | Reported |
| 2021-03-31 | $92.42M | $272.06M | $33.53M | $4.00M | $14.43M | 33.97% | 12.32% | 0.28× | Reported |
| 2020-12-31 | $97.65M | $225.11M | $36.58M | $-30.40M | $14.05M | 43.38% | 16.25% | -2.16× | Reported |
| 2020-09-30 | $103.73M | $235.47M | $38.64M | $-27.97M | $13.55M | 44.05% | 16.41% | -2.06× | Reported |
| 2020-06-30 | $110.41M | $241.07M | $43.29M | $-30.29M | $12.98M | 45.80% | 17.96% | -2.33× | Reported |
| 2020-03-31 | $122.58M | $224.41M | $48.10M | $-63.20M | $13.64M | 54.62% | 21.43% | -4.63× | Reported |
| 2019-12-31 | $132.85M | $272.26M | $57.33M | $-39.10M | $15.02M | 48.80% | 21.06% | -2.60× | Reported |
| 2019-09-30 | $140.94M | $280.42M | $64.39M | $-48.93M | $15.76M | 50.26% | 22.96% | -3.10× | Reported |
| 2019-06-30 | $147.27M | $286.69M | $72.98M | $-45.77M | $16.21M | 51.37% | 25.46% | -2.82× | Reported |
| 2019-03-31 | $153.66M | $283.54M | $79.72M | $-61.43M | $14.35M | 54.19% | 28.12% | -4.28× | Reported |
| 2018-12-31 | $164.85M | $250.99M | $86.94M | $-94.67M | $10.98M | 65.68% | 34.64% | -8.62× | Reported |
| 2018-09-30 | $176.78M | $201.52M | $93.86M | $-139.68M | (m) | 87.72% | 46.58% | (m) | (m) |
| 2018-06-30 | $189.93M | $144.97M | $99.55M | $-205.84M | (m) | 131.01% | 68.67% | (m) | (m) |
| 2018-03-31 | $199.93M | (m) | $104.32M | $-242.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $207.81M | $27.68M | $108.73M | $-292.39M | $720.00K | 750.62% | 392.76% | -406.10× | Reported |
| 2017-09-30 | $213.95M | (m) | $112.49M | $-301.69M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $216.43M | (m) | $115.75M | $-290.25M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $217.39M | (m) | $117.52M | $-278.55M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $222.80M | (m) | $117.26M | $-276.60M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $218.84M | (m) | (m) | $-265.76M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $218.79M | (m) | (m) | $-260.50M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $223.95M | (m) | (m) | $-258.93M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $208.47M | (m) | (m) | $-240.28M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $195.56M | (m) | $89.63M | $-225.84M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $175.73M | (m) | $75.12M | $-201.06M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $151.35M | (m) | $54.09M | $-175.06M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $122.92M | (m) | $39.15M | $-142.28M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $96.39M | (m) | $25.87M | $-110.67M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $76.37M | (m) | $17.23M | $-89.04M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $51.81M | (m) | $11.51M | $-62.85M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $45.05M | (m) | $7.52M | $-54.83M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $40.32M | (m) | $5.01M | $-60.79M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $46.03M | (m) | $3.57M | $-72.33M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $48.60M | (m) | $2.38M | $-74.40M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $49.64M | (m) | $1.41M | $-74.45M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | $-62.29M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | $-36.75M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | $-22.00M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $826.37K | (m) | $67.02K | $-10.16M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |